(Bloomberg) — The stakes are high for the results of Moderna Inc.’s coming Covid-19 vaccine trial. But as far as investors are concerned, the impact may already be in the price of financial assets.The bar was raised for markets to rally following an announcement by Pfizer Inc. that its vaccine protected 90% of Covid-19 cases in a study, investors and strategists said. Moderna’s version, which uses similar experimental messenger RNA technology, is due to report results imminently.The success of Pfizer’s trial has “some spillover” to Moderna because of its technological similarities, said Feifei Li, head of equities at Research Affiliates …read more
Source:: Yahoo Finance
